NCI makes major commitment to nanotechnology for cancer research


The National Cancer Institute NCI), part of the National Institutes of Health, hosts a media briefing on the formal announcement of its $144.3 million, five-year integrated initiative to develop and apply nanotechnology to cancer prevention, detection, diagnosis and treatment. Nanotechnology, the development and engineering of devices so small that they are measured on a molecular scale, has already demonstrated promising results in cancer research and treatment. NCI has invited experts from both the oncology and nanotechnology disciplines to brief reporters on the science, the issues, and the potential of the new NCI initiative, including:

  • Nanotechnology: what is it, how does it work, what's the promise?
  • The intersection of nanotechnology and cancer today and tomorrow
  • Moving nanotechnology forward: the safety and ethical considerations
  • The nation's commitment to nanotechnology


  • Dr. Andrew von Eschenbach, Director, NCI
  • Dr. Anna Barker, Deputy Director, Advanced Technologies and Strategic Partnerships, NCI
  • Dr. Richard Smalley, Nobel Laureate and Professor of Nanotechnology, Rice University
  • Dr. Mauro Ferrari, Special Expert to the NCI on Nanotechnology, Ohio State U.
  • Dr. Samuel Wickline, Director of Cardiology, Washington University
  • Dr. Janet Woodcock, Director, FDA Center for Drug Evaluation and Research
  • Dr. Vicki Colvin, Executive Director, Center for Biological and Environmental Nanotechnology and Associate Professor of Chemistry, Rice University
  • The Honorable Phillip J. Bond, Under Secretary of Commerce for Technology

Monday, September 13, 2004, 11 a.m. 12:30 p.m. EDT To register for the press briefing, please contact Dorie Hightower or Ann Benner in the NCI Press Office at (301)496-6641 or at [email protected].

National Institutes of Health, Natcher Conference Center, balcony "C" (Medical Center Station on the Metro's Red Line) Webcast live at and also available to reporters via a toll-free conference line at 1-888-428-4479 (Code name: NCI Nanotech) in the United States only.

The briefing will begin promptly at 11 a.m. Reporters should log-on to the webcast and/or dial into the tele- briefing 5-10 minutes before the start of the conference. To ask questions during the tele-briefing, press *1 on your touchtone phone; to withdraw your question, press *2. You may queue up at anytime. You will hear a tone to indicate your question is pending. Instructions for asking questions via the webcast will be on the webcast site. The full webcast and a transcript of the briefing will be available the afternoon following the media briefing at the Web site

Source: Eurekalert & others

Last reviewed: By John M. Grohol, Psy.D. on 21 Feb 2009
    Published on All rights reserved.